Bayer Reports Positive Safety Data on Parkinson's Disease Drug
BAYRY's experimental Parkinson's disease drug continues to show a favorable safety profile in all 12 participants in the trial's high and low-dose cohorts at 24 months.
MustGrow Biologics CEO discusses commercial expansion, Bayer partnership - ICYMI
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) CEO Corey Giasson joined Proactive to chat about the company's transition to commercialization from its R&D focus. He noted the commercialization of its biofertility product TerraSante, which has gained momentum in key US states.
Bayer Submits Application for Label Expansion of Prostate Cancer Drug
BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Bayer (BAYRY) Moves to Buy: Rationale Behind the Upgrade
Bayer (BAYRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg
BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.
Bayer: Speculative Value Beyond Litigation Pressures
Bayer's Q2 2024 results were mixed, with strong Pharmaceuticals performance offsetting challenges in Crop Science and stable Consumer Health results. The reaffirmation of full-year guidance and a significant legal win in the "Schaffner vs. Monsanto" case offer some reassurance to investors. Under all the litigation noise, Bayer is still a strong, innovative business, with potential in both agriculture and pharma.
Bayer Presents Encouraging Data From Late-Stage Cardiovascular Study
BAYRY's late-stage FINEARTS-HF study on finerenone show statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure.
Bayer Initiates Late-Stage Study on Investigational NSCLC Drug
BAYRY enrolls the first patient in the phase III SOHO-02 study among treatment-na??ve patients with advanced NSCLC with HER2-activating mutations.
Bayer, NextRNA to Develop Therapeutics Targeting Oncology
BAYRY collaborates with NextRNA Therapeutics to develop small molecule therapeutics targeting lncRNAs in oncology.
Bayer (BAYRY) Starts Mid-Stage Study on Chronic Kidney Disease Drug
Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.
Appeals Court Rules in Favor of Bayer-Owned Monsanto in Roundup Cancer Case
In a big victory for Bayer-owned Monsanto, a federal court overturned a verdict finding the company responsible over claims its Roundup weed killer causes cancer.
Bayer wins big US legal victory against Roundup cancer claims; shares surge
Bayer won a big legal victory in its fight to limit liability from claims its Roundup weed killer causes cancer, as a U.S. appeals court on Thursday said federal law shields the German company from a lawsuit by a Pennsylvania landscaper.
